Press Release

New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials

Jan 12, 2021 | Press Release

OX2 Therapeutics has begun a Phase I clinical trial for a first-of-its-kind immunotherapy targeting aggressive brain tumors, aiming to boost the immune system and improve outcomes for patients.

FDA Grants IND Approval to OX2 Therapeutics to Initiate Phase I Clinical Trial of Its Peptide Checkpoint Modulator for Patients with CNS Tumors

Jun 7, 2020 | Press Release, Featured

FDA Grants IND Approval to OX2 Tx to Proceed in a Phase I Clinical trial of its Peptide Checkpoint Inhibitor for Patients with Central Nervous System Tumors MINNEAPOLIS, MN, USA, June 8, 2020 /EINPresswire.com/ — OX2 Therapeutics, Inc, a privately held Minneapolis...